[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Keith Abrams posts on X about $hrmy, $urgn, $idya, $bcrx the most. They currently have XXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.
Social category influence finance XXXX%
Social topic influence $hrmy 3.13%, $urgn #3, $idya 3.13%, $bcrx #7, printing 1.56%, money 1.56%, decent 1.56%, $cgon 1.56%, $rgti 1.56%, $atxs XXXX%
Top accounts mentioned or mentioned by @berlinergy @coti36762360 @jeff_walenta @buffalo51766917 @bokhzam @aaronrosenblum5 @sharkbiotech @bo_khzam @65 @ahoriginal @biosntechs @quantumup1 @lblegend33 @miljenkoz @binarypharmer @monacobiotech @andreagtc @avidresearch @richardtip17589 @stevewagsinvest
Top assets mentioned IDEAYA Biosciences, Inc. Common Stock (IDYA) CG Oncology, Inc. Common stock (CGON) Rigetti Computing, Inc. Common Stock (RGTI)
Top posts by engagements in the last XX hours
"$HRMY: Fragile X was to me a "free call" given that it's been a graveyard for drug dev'l. However $HRMY is dirt cheap - EV/prod revenue = XXX for 2025 XXX for 2026. Those values are rarely seen in biotech They're still printing money and have a decent pipeline. Not selling"
X Link @DeepSouthDoctor 2025-09-24T17:57Z 4033 followers, 1684 engagements
"Can anybody tell me why $CGON deserves to have an Enterprise Value 3x $URGN"
X Link @DeepSouthDoctor 2025-10-05T23:54Z 4034 followers, 1542 engagements
"$RGTI: One of these days I might short the stock. Hard to do when it hasn't declined for X consecutive days in a long time"
X Link @DeepSouthDoctor 2025-10-15T13:41Z 4034 followers, 1569 engagements
"$IDYA - I remain a fan of the company after reading yesterday's transcript and reviewing the slide deck. Well capitalized with several "shots on goal" solid science and some impressive early data"
X Link @DeepSouthDoctor 2025-09-09T13:52Z 4030 followers, 1528 engagements
"$BCRX: Read the CC transcript re: $ATXS deal. If Ph3 LAI drug is approvable (data Q127) I like the deal. Company est. 2029 $1B cash balance $1B+ revenue (going to $1.8B in 2033). Early pipeline and possible add'l future BD a potential bonus. All in all it's a solid l-t buy"
X Link @DeepSouthDoctor 2025-10-15T12:50Z 4034 followers, 4483 engagements
"Current holdings in order of size: $RZLT (YE Ph3 data) $TCMD (EV/prod rev 1.0) $IDYA (YE Ph3 data deep pipeline) $URGN (fairly valued) $ABEO (2026 EV/prod rev 1.0) $HRMY ('26 EV/prod rev 1.0) $TECX (EV $X Oct Ph1b data) $BCRX ('26 EV/prod rev 2.0)"
X Link @DeepSouthDoctor 2025-10-06T13:00Z 4034 followers, 3317 engagements